94 related articles for article (PubMed ID: 11474564)
1. [Prognosis of acute lymphoblastic leukemia in children. Results of the French protocol FRALLE 93].
Schaison G; Auclerc MF; Baruchel A; Leblanc T; Leverger G
Bull Acad Natl Med; 2001; 185(1):149-60; discussion 160-2. PubMed ID: 11474564
[TBL] [Abstract][Full Text] [Related]
2. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials.
Boissel N; Auclerc MF; Lhéritier V; Perel Y; Thomas X; Leblanc T; Rousselot P; Cayuela JM; Gabert J; Fegueux N; Piguet C; Huguet-Rigal F; Berthou C; Boiron JM; Pautas C; Michel G; Fière D; Leverger G; Dombret H; Baruchel A
J Clin Oncol; 2003 Mar; 21(5):774-80. PubMed ID: 12610173
[TBL] [Abstract][Full Text] [Related]
3. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome.
Ballerini P; Landman-Parker J; Cayuela JM; Asnafi V; Labopin M; Gandemer V; Perel Y; Michel G; Leblanc T; Schmitt C; Fasola S; Hagemejier A; Sigaux F; Auclerc MF; Douay L; Leverger G; Baruchel A
Haematologica; 2008 Nov; 93(11):1658-65. PubMed ID: 18835836
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of karyotypic analysis in children and adults with high-risk acute lymphoblastic leukemia included in the PETHEMA ALL-93 trial.
Ribera JM; Ortega JJ; Oriol A; Granada I; Hernández-Rivas JM; Parody R; Bethencourt C; Rivas C; Bastida P; del Potro E; González-Valentín ME; Moreno MJ; Besalduch J; Fernández-Calvo J; Tormo M; Arias J; Molinés A; Sanz MA; Maldonado J; Millá F; Feliu E; San Miguel JF;
Haematologica; 2002 Feb; 87(2):154-66. PubMed ID: 11836166
[TBL] [Abstract][Full Text] [Related]
5. Prognostic study of continuous variables (white blood cell count, peripheral blast cell count, haemoglobin level, platelet count and age) in childhood acute lymphoblastic leukaemia. Analysis Of a population of 1545 children treated by the French Acute Lymphoblastic Leukaemia Group (FRALLE).
Donadieu J; Auclerc MF; Baruchel A; Perel Y; Bordigoni P; Landman-Parker J; Leblanc T; Cornu G; Sommelet D; Leverger G; Schaison G; Hill C;
Br J Cancer; 2000 Dec; 83(12):1617-22. PubMed ID: 11104555
[TBL] [Abstract][Full Text] [Related]
6. [Prognostic factors for childhood acute non-mature B-lymphoblastic leukemia].
Jiang H; Gu LJ; Xue HL; Tang JY; Chen J; Pan C; Chen J; Xu C; Dong L; Zhou M
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):290-4. PubMed ID: 18554450
[TBL] [Abstract][Full Text] [Related]
7. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
[TBL] [Abstract][Full Text] [Related]
8. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95.
Möricke A; Zimmermann M; Reiter A; Gadner H; Odenwald E; Harbott J; Ludwig WD; Riehm H; Schrappe M
Klin Padiatr; 2005; 217(6):310-20. PubMed ID: 16307416
[TBL] [Abstract][Full Text] [Related]
10. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors for leukemic induction failure in children with acute lymphoblastic leukemia and outcome after salvage therapy: the FRALLE 93 study.
Oudot C; Auclerc MF; Levy V; Porcher R; Piguet C; Perel Y; Gandemer V; Debre M; Vermylen C; Pautard B; Berger C; Schmitt C; Leblanc T; Cayuela JM; Socie G; Michel G; Leverger G; Baruchel A
J Clin Oncol; 2008 Mar; 26(9):1496-503. PubMed ID: 18349402
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.
Bader P; Kreyenberg H; Henze GH; Eckert C; Reising M; Willasch A; Barth A; Borkhardt A; Peters C; Handgretinger R; Sykora KW; Holter W; Kabisch H; Klingebiel T; von Stackelberg A;
J Clin Oncol; 2009 Jan; 27(3):377-84. PubMed ID: 19064980
[TBL] [Abstract][Full Text] [Related]
13. Treatment results of childhood acute lymphoblastic leukemia in Austria--a report of 20 years' experience.
Attarbaschi A; Mann G; Dworzak M; Urban C; Fink FM; Dieckmann K; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Feb; 114(4):148-57. PubMed ID: 12060981
[TBL] [Abstract][Full Text] [Related]
14. Treatment of children with acute lymphoblastic leukemia in India using a BFM protocol.
Bajel A; George B; Mathews V; Viswabandya A; Kavitha ML; Srivastava A; Chandy M
Pediatr Blood Cancer; 2008 Nov; 51(5):621-5. PubMed ID: 18688848
[TBL] [Abstract][Full Text] [Related]
15. Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study.
Madzo J; Zuna J; Muzíková K; Kalinová M; Krejcí O; Hrusák O; Otová B; Starý J; Trka J
Cancer; 2003 Jan; 97(1):105-13. PubMed ID: 12491511
[TBL] [Abstract][Full Text] [Related]
16. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
[TBL] [Abstract][Full Text] [Related]
17. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
[TBL] [Abstract][Full Text] [Related]
18. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
[TBL] [Abstract][Full Text] [Related]
19. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
[TBL] [Abstract][Full Text] [Related]
20. Evolution of BFM trials for childhood ALL.
Schrappe M
Ann Hematol; 2004; 83 Suppl 1():S121-3. PubMed ID: 15124702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]